OverviewChartProfileKey statisticsFinancialsTechnicalNews
Derivatives
TraderScreen

MORPHOSYS AG O.N./  DE0006632003  /

Xetra
2024-06-03  5:35:05 PM Chg. 0.00 Volume Bid2024-06-03 Ask5:35:05 PM Market Capitalization Dividend Y. P/E Ratio
68.65EUR 0.00% 115,734
Turnover: 7.87 mill.		 -Bid Size: - -Ask Size: - 2.58 bill.EUR - -
TeleTrader 04-11 Novartis launches offer for Morphosys at €68 per share
TeleTrader 03-12 Germany clears Novartis' MorphoSys $2.9B deal
TeleTrader 02-05 Novartis to acquire MorphoSys for $2.9B
GlobeNewswire 2021-06-03 CONSTELLATION ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of CNST and Encourages Investors ...
GlobeNewswire 2021-06-02 Royalty Pharma Announces $2.025 Billion Strategic Funding Partnership With MorphoSys
GlobeNewswire 2020-04-27 I-Mab and MorphoSys Announce First Patient Dosed in Phase 3 Clinical Trial of TJ202/MOR202 in r/r Mu...
GlobeNewswire 2019-10-28 MOR106 clinical development in atopic dermatitis stopped for futility
GlobeNewswire 2019-04-23 Galapagos and MorphoSys announce initiation of GECKO Phase 2 study with MOR106 in atopic dermatitis ...
GlobeNewswire 2019-04-23 Galapagos and MorphoSys announce initiation of GECKO Phase 2 study with MOR106 in atopic dermatitis ...
GlobeNewswire 2018-09-13 Galapagos and MorphoSys announce start of a Phase 1 subcutaneous bridging study with MOR106
GlobeNewswire 2018-09-13 Galapagos and MorphoSys announce start of a Phase 1 subcutaneous bridging study with MOR106
GlobeNewswire 2018-09-12 MorphoSys and Galapagos announce U.S. Antitrust Clearance for global license agreement for MOR106 wi...
GlobeNewswire 2018-09-12 MorphoSys and Galapagos announce U.S. Antitrust Clearance for global license agreement for MOR106 wi...
GlobeNewswire 2018-07-19 MorphoSys and Galapagos Sign Global License Agreement for MOR106 with Top Pharma Partner
GlobeNewswire 2018-07-19 MorphoSys and Galapagos Sign Global License Agreement for MOR106 with Top Pharma Partner
GlobeNewswire 2018-05-01 Galapagos and MorphoSys announce initiation of the IGUANA Phase 2 clinical trial with MOR106 in atop...
GlobeNewswire 2018-05-01 Galapagos and MorphoSys announce initiation of the IGUANA Phase 2 clinical trial with MOR106 in atop...
GlobeNewswire 2018-04-19 Nasdaq Welcomes MorphoSys AG (Nasdaq: MOR) to The Nasdaq Stock Market
GlobeNewswire 2018-02-17 Galapagos and MorphoSys present results from a Phase 1 study with MOR106 in atopic dermatitis as lat...
GlobeNewswire 2018-02-17 Galapagos and MorphoSys present results from a Phase 1 study with MOR106 in atopic dermatitis as lat...
GlobeNewswire 2017-09-27 Galapagos and MorphoSys report first promising signs of clinical activity in a Phase 1 study with IL...
GlobeNewswire 2017-09-27 Galapagos and MorphoSys report first promising signs of clinical activity in a Phase 1 study with IL...
GlobeNewswire 2017-08-31 Aptevo Therapeutics and MorphoSys End Joint Development and Commercialization Agreement for MOR209/E...
GlobeNewswire 2016-12-15 Aptevo Therapeutics Amends Collaboration Agreement with MorphoSys AG for Novel Immunotherapeutic, MO...
GlobeNewswire 2016-12-13 MorphoSys Starts Phase 2 Trial of MOR208 in Combination with Idelalisib in Patients with Relapsed or...